Trial result ·
Optimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This trial tested a personalised way to give 177Lu-DOTATATE for neuroendocrine tumours. These tumours had spread mainly to the liver and could not be removed by surgery. The drug was given in 4 cycles, every 2 mo. The initial 2 cycles went into the liver artery. The next 2 cycles went into a vein. The dose was adjusted by liver volume. The team checked safety, radiation protection and dosimetry. They compared the artery route with the vein route.
What they found
Giving the drug into the artery was feasible in all patients. Staff and patients had radiation exposure within legal limits. There were no contamination events. The artery route gave a dose over 3-fold higher to liver spread. The comparison was with the vein route. Interim response may have played a part. PET imaging showed an 86 per 100 rise in liver lesion uptake. This was with the artery route. Only 1 severe adverse event was reported, a low esophageal tear. It was not attributed to the route. Partial response was seen in 67 per 100 patients 3 mo after treatment. It rose to 87 per 100 at 6 mo.
What it means for patients
The authors say the artery-then-vein plan was feasible and safe. They say the personalised, volume-based approach gave higher uptake and doses in liver spread. They say response rates were high and the whole body stayed covered.
Why it is not certain yet
This was a small trial. The abstract says interim response could have affected the dose comparison. It describes no comparison group for response. The abstract calls the efficacy findings preliminary. A small trial can only show so much.
Source
Optimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.
PubMed · PMID 42785954We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Neuroendocrine tumours publications